Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gynecology

PUBLISHER: Grand View Research | PRODUCT CODE: 1404753

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1404753

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (North America, Europe, Latin America), And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

  • Based on treatment, the dietary supplements treatment segment dominated the market in 2023 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
  • The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
  • North America held the largest revenue share in 2023. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
  • In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
  • In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms
Show more
Product Code: GVR-4-68039-434-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Growing number of women undergoing menopause
    • 3.4.2. Increasing awareness about menopause and its treatment
    • 3.4.3. Growing opportunities and innovations in menopause treatment
    • 3.4.4. Increasing research supporting advantages of dietary supplements
  • 3.5. Market Restraint Analysis
    • 3.5.1. Social stigma associated with menopause and adverse effects of products
    • 3.5.2. Lack of well-defined regulations
  • 3.6. Business Environment Analysis
    • 3.6.1. PESTLE Analysis
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis

  • 4.1. Menopause Market: Treatment Movement Analysis
  • 4.2. Dietary Supplements
    • 4.2.1. Dietary Supplements Market, 2018 - 2030 (USD Million)
  • 4.3. OTC Pharma Products
    • 4.3.1. OTC Pharma Products Market, 2018 - 2030 (USD Million)
    • 4.3.2. Hormonal Products
      • 4.3.2.1.1. Hormonal Products Market, 2018 - 2030 (USD Million)
    • 4.3.3. Non-hormonal Products
      • 4.3.3.1.1. Non-hormonal Products Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Menopause Market Share By Region, 2023 & 2030
  • 5.2. North America
    • 5.2.1. North America Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Regulatory Framework/Scenario
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. U.S. Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Regulatory Framework/Scenario
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Canada Menopause Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Regulatory Framework/Scenario
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Germany Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Regulatory Framework/Scenario
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. UK Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Regulatory Framework/Scenario
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. France Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Regulatory Framework/Scenario
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Italy Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Regulatory Framework/Scenario
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Spain Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.7. Sweden
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Regulatory Framework/Scenario
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Sweden Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.8. Norway
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Regulatory Framework/Scenario
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Norway Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.9. Denmark
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Regulatory Framework/Scenario
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Denmark Menopause Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework/Scenario
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Japan Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework/Scenario
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. China Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework/Scenario
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. India Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Regulatory Framework/Scenario
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Australia Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.6. Thailand
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Regulatory Framework/Scenario
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Thailand Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.7. South Korea
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Regulatory Framework/Scenario
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. South Korea Menopause Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework/Scenario
      • 5.5.2.3. Competitive Scenario
      • 5.5.2.4. Brazil Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework/Scenario
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Mexico Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.4. Argentina
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework/Scenario
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Argentina Menopause Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. MEA Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework/Scenario
      • 5.6.2.3. Competitive Scenario
      • 5.6.2.4. South Africa Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework/Scenario
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Saudi Arabia Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework/Scenario
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. UAE Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework/Scenario
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Kuwait Menopause Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
    • 6.2.1. Merger& Acquisition
    • 6.2.2. Collaborations
    • 6.2.3. New Product Launch
  • 6.3. Participant's overview
    • 6.3.1. Bayer AG
      • 6.3.1.1. Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Theramex
      • 6.3.2.1. Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Abbvie Inc.
      • 6.3.3.1. Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Abbott
      • 6.3.4.1. Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Pure Encapsulations, LLC
      • 6.3.5.1. Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Dr. Reddy's Laboratories Ltd.
      • 6.3.6.1. Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Rainbow Light
      • 6.3.7.1. Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. PADAGIS LLC
      • 6.3.8.1. Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product Benchmarking
      • 6.3.8.4. Strategic Initiatives
Show more
Product Code: GVR-4-68039-434-2

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. Global dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 4. Global OTC pharma products market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 5. North America menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 6. North America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 7. U.S. menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 8. U.S. menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 9. Canada menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 10. Canada menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 11. Europe menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 12. Europe menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 13. UK menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 14. UK menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 15. Germany menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 16. Germany menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 17. France menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 18. France menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 19. Italy menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 20. Italy menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 21. Spain menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 22. Spain menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 23. Austria menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 24. Austria menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 25. Asia Pacific menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 26. Asia Pacific menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 27. China menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 28. China menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 29. Japan menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 30. Japan menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 31. India menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 32. India menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 33. South Korea menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 34. South Korea menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 35. Latin America menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 36. Latin America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 37. Brazil menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 38. Brazil menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 39. Mexico menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 40. Mexico menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 41. Middle East & Africa (MEA) menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 42. Middle East & Africa (MEA) menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 43. South Africa menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 44. South Africa menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig 1. Menopause market segmentation
  • Fig 2. Market research process
  • Fig 3. Information procurement
  • Fig 4. Primary research pattern
  • Fig 5. Market research approaches
  • Fig 6. Value - chain - based sizing & forecasting
  • Fig 7. QFD modeling for market share assessment
  • Fig 8. Market formulation & validation
  • Fig 9. Menopause market outlook 2023 (USD Million)
  • Fig 10. Penetration & growth prospect mapping
  • Fig 11. Market driver relevance analysis (Current & future impact)
  • Fig 12. Market restraint relevance analysis (Current & future impact)
  • Fig 13. Menopause market: Treatment movement analysis
  • Fig 14. Menopause market treatment outlook: Key takeaways
  • Fig 15. Dietary supplements market, 2018 - 2030 (USD Million)
  • Fig 16. OTC pharma products market, 2018 - 2030 (USD Million)
  • Fig 17. Hormonal products market, 2018 - 2030 (USD Million)
  • Fig 18. Non - hormonal products market, 2018 - 2030 (USD Million)
  • Fig 19. Regional marketplace: key takeaways
  • Fig 20. Regional outlook, 2023 & 2030
  • Fig 21. Global menopause market: region movement analysis
  • Fig 22. North America menopause market, 2018 - 2030 (USD Million)
  • Fig 23. U.S. key country dynamics
  • Fig 24. U.S. menopause market, 2018 - 2030 (USD Million)
  • Fig 25. Canada key country dynamics
  • Fig 26. Canada menopause market, 2018 - 2030 (USD Million)
  • Fig 27. Europe menopause market, 2018 - 2030 (USD Million)
  • Fig 28. UK key country dynamics
  • Fig 29. UK menopause market, 2018 - 2030 (USD Million)
  • Fig 30. Germany key country dynamics
  • Fig 31. Germany menopause market, 2018 - 2030 (USD Million)
  • Fig 32. France key country dynamics
  • Fig 33. France menopause market, 2018 - 2030 (USD Million)
  • Fig 34. Italy key country dynamics
  • Fig 35. Italy menopause market, 2018 - 2030 (USD Million)
  • Fig 36. Spain key country dynamics
  • Fig 37. Spain menopause market, 2018 - 2030 (USD Million)
  • Fig 38. Sweden key country dynamics
  • Fig 39. Sweden menopause market, 2018 - 2030 (USD Million)
  • Fig 40. Norway key country dynamics
  • Fig 41. Norway menopause market, 2018 - 2030 (USD Million)
  • Fig 42. Denmark key country dynamics
  • Fig 43. Denmark menopause market, 2018 - 2030 (USD Million)
  • Fig 44. Asia Pacific menopause market, 2018 - 2030 (USD Million)
  • Fig 45. Japan key country dynamics
  • Fig 46. Japan menopause market, 2018 - 2030 (USD Million)
  • Fig 47. China key country dynamics
  • Fig 48. China menopause market, 2018 - 2030 (USD Million)
  • Fig 49. India key country dynamics
  • Fig 50. India menopause market, 2018 - 2030 (USD Million)
  • Fig 51. Australia key country dynamics
  • Fig 52. Australia menopause market, 2018 - 2030 (USD Million)
  • Fig 53. Thailand key country dynamics
  • Fig 54. Thailand menopause market, 2018 - 2030 (USD Million)
  • Fig 55. South Korea key country dynamics
  • Fig 56. South Korea menopause market, 2018 - 2030 (USD Million)
  • Fig 57. Latin America menopause market, 2018 - 2030 (USD Million)
  • Fig 58. Brazil key country dynamics
  • Fig 59. Brazil menopause market, 2018 - 2030 (USD Million)
  • Fig 60. Mexico key country dynamics
  • Fig 61. Mexico menopause market, 2018 - 2030 (USD Million)
  • Fig 62. Argentina key country dynamics
  • Fig 63. Argentina menopause market, 2018 - 2030 (USD Million)
  • Fig 64. Middle East and Africa menopause market, 2018 - 2030 (USD Million)
  • Fig 65. South Africa key country dynamics
  • Fig 66. South Africa menopause market, 2018 - 2030 (USD Million)
  • Fig 67. Saudi Arabia key country dynamics
  • Fig 68. Saudi Arabia menopause market, 2018 - 2030 (USD Million)
  • Fig 69. UAE key country dynamics
  • Fig 70. UAE menopause market, 2018 - 2030 (USD Million)
  • Fig 71. Kuwait key country dynamics
  • Fig 72. Kuwait menopause market, 2018 - 2030 (USD Million)
  • Fig 73. Company market position analysis
  • Fig 74. Company/competition categorization
  • Fig 75. Strategy mapping
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!